One partner for comprehensive precision MRD in hematologic and solid tumors
Introducing the new MRD solution!
AML NanoMRD™: Deeper MRD insights in just 3 days to accelerate hematologic clinical trials, even with limited sample input
Right technology. Right tumor. Precision MRD.
With over a decade of supporting 300 + biopharma partners, NeoGenomics is a trusted leader in empowering biopharma partners in minimal/molecular residual disease to accelerate their clinical and translational programs across hematologic & solid tumors.
- MRD solutions across tumor types and development stages
- Detect disease before imaging to enable earlier intervention ahead of relapse
- High-sensitivity quantification of low-level disease for treatment monitoring and relapse-risk assessment
- Rigorous quality controlled, validated assays
Flow cytometry-based MRD
Tab content
NGS-based MRD
Tab content
Expertise You Can Trust. Resources You Can Act On.
Explore our webinars, white papers, and other valuable resources
CTA style
Default